E Seregni

Summary

Affiliation: Istituto Nazionale Tumori
Country: Italy

Publications

  1. ncbi A female survivor of childhood medulloblastoma presenting with growth-hormone-induced edema and inflammatory lesions: a case report
    Veronica Biassoni
    Department of Pediatric Oncology, Fondazione IRCCS Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian 1, 20133 Milan, Italy
    J Med Case Reports 3:17. 2009
  2. ncbi Treatment with tandem [(90)Y]DOTA-TATE and [(177)Lu] DOTA-TATE of neuroendocrine tumors refractory to conventional therapy: preliminary results
    E Seregni
    Nuclear Medicine, National Cancer Institute, Milan, Italy
    Q J Nucl Med Mol Imaging 54:84-91. 2010
  3. ncbi Circulating tumour markers in breast cancer
    Ettore Seregni
    Radioisotopes Laboratory, Nuclear Medicine Division, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian 1, 20133 Milan, Italy
    Eur J Nucl Med Mol Imaging 31:S15-22. 2004
  4. ncbi Redifferentiating agents in non-radioiodine avid cancer
    E Seregni
    Nuclear Medicine Division, Department of Diagnostic Imaging and Radiotherapy, Fondazione IRCCS National Cancer Institute, Milan, Italy
    Q J Nucl Med Mol Imaging 53:513-9. 2009
  5. ncbi Osteoprotegerin and osteopontin serum values in postmenopausal advanced breast cancer patients treated with anastrozole
    A Martinetti
    Nuclear Medicine Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Endocr Relat Cancer 11:771-9. 2004
  6. ncbi Clinical significance of blood chromogranin A measurement in neuroendocrine tumours
    E Seregni
    Nuclear Medicine Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Ann Oncol 12:S69-72. 2001
  7. ncbi Biological activity of anastrozole in postmenopausal patients with advanced breast cancer: effects on estrogens and bone metabolism
    E Bajetta
    Medical Oncology Unit B and Nuclear Medicine Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Ann Oncol 13:1059-66. 2002
  8. ncbi Accuracy and clinical correlates of two different methods for chromogranin A assay in neuroendocrine tumors
    L Ferrari
    Nuclear Medicine Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Int J Biol Markers 19:295-304. 2004
  9. ncbi (131)I-MIBG treatment of pheochromocytoma: low versus intermediate activity regimens of therapy
    M R Castellani
    Nuclear Medicine Division, National Cancer Institute, Milan, Italy
    Q J Nucl Med Mol Imaging 54:100-13. 2010
  10. ncbi Clinical utility of biochemical marker of bone remodelling in patients with bone metastases of solid tumors
    E Seregni
    Nuclear Medicine Division Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Q J Nucl Med 45:7-17. 2001

Collaborators

Detail Information

Publications56

  1. ncbi A female survivor of childhood medulloblastoma presenting with growth-hormone-induced edema and inflammatory lesions: a case report
    Veronica Biassoni
    Department of Pediatric Oncology, Fondazione IRCCS Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian 1, 20133 Milan, Italy
    J Med Case Reports 3:17. 2009
    ..There are few reports, however, on the "in-vivo" induction of edema and symptomatic inflammatory lesions during replacement therapy...
  2. ncbi Treatment with tandem [(90)Y]DOTA-TATE and [(177)Lu] DOTA-TATE of neuroendocrine tumors refractory to conventional therapy: preliminary results
    E Seregni
    Nuclear Medicine, National Cancer Institute, Milan, Italy
    Q J Nucl Med Mol Imaging 54:84-91. 2010
    ..Aim of this study was to evaluate the feasibility, the efficacy and the toxicity of this treatment in neuroendocrine tumors expressing somatostatin receptors relapsed or refractory to conventional therapies...
  3. ncbi Circulating tumour markers in breast cancer
    Ettore Seregni
    Radioisotopes Laboratory, Nuclear Medicine Division, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian 1, 20133 Milan, Italy
    Eur J Nucl Med Mol Imaging 31:S15-22. 2004
    ..Furthermore, research studies are ongoing to identify and validate new biochemical parameters which can be of use not only in advanced disease but also in other stages of the diagnostic work-up of breast cancer...
  4. ncbi Redifferentiating agents in non-radioiodine avid cancer
    E Seregni
    Nuclear Medicine Division, Department of Diagnostic Imaging and Radiotherapy, Fondazione IRCCS National Cancer Institute, Milan, Italy
    Q J Nucl Med Mol Imaging 53:513-9. 2009
    ..This review will discuss the results of the most recent studies on drugs with redifferentiating properties and their application in patients with radioiodine refractory thyroid cancer...
  5. ncbi Osteoprotegerin and osteopontin serum values in postmenopausal advanced breast cancer patients treated with anastrozole
    A Martinetti
    Nuclear Medicine Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Endocr Relat Cancer 11:771-9. 2004
    ..OPG and OPN appear to be useful predictors of the outcome of skeletal disease and elevated OPN values may be associated with short survival in advanced breast cancer patients...
  6. ncbi Clinical significance of blood chromogranin A measurement in neuroendocrine tumours
    E Seregni
    Nuclear Medicine Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Ann Oncol 12:S69-72. 2001
    ..CgA evaluation is recommended in the follow-up of patients with such tumours...
  7. ncbi Biological activity of anastrozole in postmenopausal patients with advanced breast cancer: effects on estrogens and bone metabolism
    E Bajetta
    Medical Oncology Unit B and Nuclear Medicine Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Ann Oncol 13:1059-66. 2002
    ..To study the short-term biological effect of anastrozole on serum estrogens, androgens, 17-hydroxyprogesterone (17OH-PGR), gonadotrophins, sex hormone binding globulin (SHBG) and bone metabolism markers...
  8. ncbi Accuracy and clinical correlates of two different methods for chromogranin A assay in neuroendocrine tumors
    L Ferrari
    Nuclear Medicine Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Int J Biol Markers 19:295-304. 2004
    ..This makes it difficult to compare CgA values measured with different kits and affects the clinical accuracy of the different assays for CgA...
  9. ncbi (131)I-MIBG treatment of pheochromocytoma: low versus intermediate activity regimens of therapy
    M R Castellani
    Nuclear Medicine Division, National Cancer Institute, Milan, Italy
    Q J Nucl Med Mol Imaging 54:100-13. 2010
    ..Aim of the present study was to compare the use of low versus intermediate activity of MIBG to achieve better results in a shorter time with higher activities...
  10. ncbi Clinical utility of biochemical marker of bone remodelling in patients with bone metastases of solid tumors
    E Seregni
    Nuclear Medicine Division Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Q J Nucl Med 45:7-17. 2001
    ..Also the cellular and molecular bases of bone remodelling are reported with details...
  11. ncbi Individualized dosimetry in the management of metastatic differentiated thyroid cancer
    C Chiesa
    Nuclear Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
    Q J Nucl Med Mol Imaging 53:546-61. 2009
    ....
  12. ncbi Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkin's lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin)
    C Chiesa
    Nuclear Medicine Division, Foundation IRCCS Istituto Nazionale Tumori, 20133 Milan, Italy
    Eur J Nucl Med Mol Imaging 36:1745-57. 2009
    ....
  13. ncbi Diagnostic and prognostic tumor markers in the gastrointestinal tract
    E Seregni
    Nuclear Medicine Division, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Semin Surg Oncol 20:147-66. 2001
    ..In this work, the main molecular, genetic, tissular, and circulating tumor markers proposed for diagnosis and prognosis of gastrointestinal malignancies are reviewed and discussed...
  14. ncbi [Radioisotopic imaging of neuroendocrine tumours. Which radiopharmaceutical and which diagnostic procedure?]
    E Bombardieri
    Unità Operativa Medicina Nucleare, Istituto Nazionale Tumori Milano, Milan, Italy
    Minerva Endocrinol 26:197-213. 2001
    ..Aim of this review is to summarize the potential of nuclear medicine techniques in the diagnosis of neuroendocrine tumours and to stresses the renewed role of nuclear medicine in the management of this disease...
  15. ncbi Imaging of neuroendocrine tumours with gamma-emitting radiopharmaceuticals
    E Bombardieri
    Division of Nuclear Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
    Q J Nucl Med Mol Imaging 54:3-15. 2010
    ..This overview summarizes the state of art of NETs imaging, focusing the attention mainly on gamma-emitting tracers...
  16. ncbi Laboratory tests for neuroendocrine tumours
    E Seregni
    Nuclear Medicine Division, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Q J Nucl Med 44:22-41. 2000
    ..Particular consideration has been given to biomarkers for gastroenteropancreatic and sympatho-adrenal system tumours and for prostate and breast cancers with neuroendocrine differentiation...
  17. ncbi Position of nuclear medicine techniques in the diagnostic work-up of neuroendocrine tumors
    E Bombardieri
    Nuclear Medicine Division, Istituto Nazionale Tumori, Milan, Italy
    Q J Nucl Med Mol Imaging 48:150-63. 2004
    ..allows the interpretation of radiopharmaceutical uptake as a prognostic parameter and sometimes as a predictor of the response to treatment...
  18. ncbi Serum levels of tartrate-resistant acid phosphatase-5b in breast cancer patients treated with pamidronate
    A Martinetti
    Nuclear Medicine Division, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Int J Biol Markers 17:253-8. 2002
    ..In conclusion, a decrease in TRAP-5b serum levels may reflect the pharmacological activity of pamidronate and seems to predict pain relief and a reduction in analgesic consumption...
  19. ncbi Comparative evaluation of two methods to assay thyroglobulin serum concentrations in patients with differentiated thyroid carcinomas
    L Ferrari
    Nuclear Medicine Division, Radioisotope Laboratory, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Q J Nucl Med Mol Imaging 48:237-42. 2004
    ..5 the Tg values measured by means of HTGK-2 IRMA. CONCLUSION: The sensitivity of the Dynotest Tg-Plus IRMA appears to be similar to that of the HTGK-2 assay...
  20. ncbi State of the art of palliative therapy
    E Seregni
    Nuclear Medicine Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
    Q J Nucl Med Mol Imaging 55:411-9. 2011
    ..Some remarks on new or under developing strategies in systemic metabolic radiopharmaceutical therapy will be reported...
  21. ncbi MIBG for diagnosis and therapy of medullary thyroid carcinoma: is there still a role?
    M R Castellani
    Nuclear Medicine Division, Department of Diagnostic Imaging and Therapy, Istituto Nazionale Tumori IRCCS Foundation, Milan, Italy
    Q J Nucl Med Mol Imaging 52:430-40. 2008
    ..Improvement of efficacy can be achieved through dosimetric calculation of administered activity...
  22. ncbi Radiolabeled somatostaitin analogs in the treatment of neuroendocrine tumors: experience of the National Cancer Institute of Milano using high dose of 111In-pentetreotide in metastatic neuroendocrine gastroenteropancreatic tumors
    E Bombardieri
    Nuclear Medicine Division, Italian Trials of Medical Oncology, National Cancer Institute, Milan, Italy
    J Endocrinol Invest 26:63-9. 2003
  23. ncbi Uptake of tritiated thymidine, deoxyglucose and methionine in three lung cancer cell lines: deoxyglucose uptake mirrors tritiated thymidine uptake
    S Nerini-Molteni
    Nuclear Medicine Division, Istituto Nazionale dei Tumori, Milano, Italy
    Tumour Biol 22:92-6. 2001
    ..Although delayed, methionine uptake was also related to cell growth and its greater intensity could be of interest for clinical use...
  24. ncbi High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: an outpatient preparative regimen for autologous hematopoietic cell transplantation
    Liliana Devizzi
    Cristina Gandini Medical Oncology and Department of Nuclear Medicine, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale Tumori, Milan, Italy
    J Clin Oncol 26:5175-82. 2008
    ..To develop high-dose myeloablative therapy for CD20(+) non-Hodgkin's lymphoma (NHL) as a safe and widely applicable regimen...
  25. ncbi Effect of steroid receptors, pS2 and cathepsin D on the outcome of elderly breast cancer patients: an exploratory investigation
    D Coradini
    Division of Experimental Oncology C, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Int J Cancer 79:305-11. 1998
    ....
  26. ncbi Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours
    E Bajetta
    Medical Oncology Unit B, Istituto Nazionale per lo Studio e la Cura dei Tumori di Milano, Italy
    Ann Oncol 13:614-21. 2002
    ..The present study aimed to assess in a multidisciplinary manner the efficacy of the same regimen at intensified doses in patients with advanced NETs...
  27. ncbi A practical dead time correction method in planar activity quantification for dosimetry during radionuclide therapy
    C Chiesa
    Unit of Nuclear Medicine, National Cancer Institute IRCCS Milan, Italy
    Q J Nucl Med Mol Imaging 53:658-70. 2009
    ..A new approach for dead time correction (DTC) is here proposed. It employs planar whole-body (WB) images without the need of standard radionuclide sources or of preliminary phantom calibrations...
  28. ncbi Thyroid-stimulating hormone suppression for protection against hypothyroidism due to craniospinal irradiation for childhood medulloblastoma/primitive neuroectodermal tumor
    Maura Massimino
    Department of Pediatrics, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
    Int J Radiat Oncol Biol Phys 69:404-10. 2007
    ..Hence, our study was launched in 1998 to evaluate the protective effect of TSH suppression during CSI for medulloblastoma/primitive neuroectodermal tumor...
  29. ncbi Incident pain and analgesic consumption decrease after samarium infusion: a pilot study
    Carla Ripamonti
    Rehabilitation and Palliative Care Operative Unit, National Cancer Institute of Milan, Via Venezian, 1, Milan, Italy
    Support Care Cancer 15:339-42. 2007
    ..0 mCi/kg of samarium-153 (153-Sm) lexidronam...
  30. ncbi Papillary thyroid carcinoma of childhood and adolescence: a 30-year experience at the Istituto Nazionale Tumori in Milan
    Paola Collini
    Department of Anatomical Pathology, Istituto Nazionale Tumori, Milan, Italy
    Pediatr Blood Cancer 46:300-6. 2006
    ..Since pediatric PTCs proved highly responsive to hormone manipulation, it is worth considering a different therapeutic approach from adult cases...
  31. ncbi Conservative surgical approach for thyroid and lymph-node involvement in papillary thyroid carcinoma of childhood and adolescence
    Maura Massimino
    Unit of Pediatrics, Istituto Nazionale Tumori, Milan, Italy
    Pediatr Blood Cancer 46:307-13. 2006
    ..The aim of this study is to outline the possibility of a conservative approach (hemithyroidectomy plus selective neck dissection of clinically involved nodes, followed by TSH-suppressive therapy) in a selected group of patients...
  32. ncbi Radiation-induced thyroid changes: a retrospective and a prospective view
    Maura Massimino
    Department of Medical Oncology, Paediatrics Unit, Istituto Nazionale Tumori, Via Venezian, 1, Milan 20133, Italy
    Eur J Cancer 45:2546-51. 2009
    ..Increasing numbers of children are being cured of cancers by treatments that include radiation also involving the thyroid bed: these children warrant an early diagnosis and treatment of any radiation-related thyroid changes...
  33. ncbi Dosimetry in myeloablative (90)Y-labeled ibritumomab tiuxetan therapy: possibility of increasing administered activity on the base of biological effective dose evaluation. Preliminary results
    Carlo Chiesa
    Nuclear Medicine, National Cancer Institute, Milan, Italy
    Cancer Biother Radiopharm 22:113-20. 2007
    ..This is a conceptually more suitable parameter, as it takes into account not only the absorbed dose, but also the influence of the dose rate and of the tissue repair mechanism...
  34. ncbi Recombinant human thyrotropin (rhTSH) in the follow-up and treatment of patients with thyroid cancer
    Emilio Bombardieri
    Nuclear Medicine Division, National Cancer Institute, Milan, Italy
    Tumori 89:533-6. 2003
    ..A recent clinical prospective trial has been proposed by the Thyroid Cancer Study Group of the Istituto Nazionale Tumori and is now ongoing...
  35. ncbi Biochemical characteristics and clinical applications of alpha-fetoprotein isoforms
    E Seregni
    Nuclear Medicine Department, National Cancer Institute, Milan, Italy
    Anticancer Res 15:1491-9. 1995
    ..In this review the molecular basis of AFP microheterogeneity and the clinical application of AFP isoforms will be discussed...
  36. ncbi Need, feasibility and convenience of dosimetric treatment planning in liver selective internal radiation therapy with (90)Y microspheres: the experience of the National Tumor Institute of Milan
    C Chiesa
    Department of Nuclear Medicine, National Cancer Institute, IRCCS Foundation, Milan, Italy
    Q J Nucl Med Mol Imaging 55:168-97. 2011
    ..Second, for HCC patients, progression of both cancer and cirrhosis can simulate a radioinduced toxicity, making the analysis more complex...
  37. ncbi Structure, function and gene expression of epithelial mucins
    E Seregni
    Nuclear Medicine Department, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan
    Tumori 83:625-32. 1997
    ..The MUC6 gene is expressed by gastric tissue and, recently, MUC7 has been cloned and sequenced using a salivary cDNA library...
  38. ncbi Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management
    M Greco
    General Surgery B--Breast Unit, National Cancer Institute, Via Venezian 1, 20133 Milan, Italy
    J Natl Cancer Inst 93:630-5. 2001
    ..These results should be confirmed in large multicenter studies...
  39. ncbi Short-term effects of anastrozole treatment on insulin-like growth factor system in postmenopausal advanced breast cancer patients
    L Ferrari
    Nuclear Medicine, Istituto Nazionale per lo Studio e la Cura dei Tumori of Milan, Via G. Venezian, 1, 20133 Milan, Italy
    J Steroid Biochem Mol Biol 80:411-8. 2002
    ....
  40. ncbi Thyroid carcinoma associated with squamous cell carcinoma of the head and neck: which policy?
    Marco Guzzo
    Otorhinolaryngology Unit, Istituto Nazionale Tumori, Milan, Italy
    Head Neck 29:33-7. 2007
    ..Thyroid carcinoma occurring as a second primary associated with head and neck squamous cell carcinoma (HNSCC) is unusual. The clinical management of thyroid cancer in such cases has been debated...
  41. ncbi 90Y Labeling of monoclonal antibody MOv18 and preclinical validation for radioimmunotherapy of human ovarian carcinomas
    Angela Coliva
    Unit of Nuclear Medicine, Istituto Nazionale Tumori, Via Venezian 1, 20133 Milano, Italy
    Cancer Immunol Immunother 54:1200-13. 2005
    ....
  42. ncbi Serum and cerebrospinal fluid human chorionic gonadotropin (hCG) and alpha-fetoprotein (AFP) in intracranial germ cell tumors
    E Seregni
    RIA Laboratory, Nuclear Medicine Division, Istituto Nazionale per la Studio e la Cura dei Tumori, Milan, Italy
    Int J Biol Markers 17:112-8. 2002
    ..We conclude that these two markers, and mostly betahCG, may be useful in the diagnosis and monitoring of the response to therapy of patients with intracranial germ cell tumors...
  43. ncbi Thyroid iatrogenic sequelae after the treatment of pediatric cancer
    M Massimino
    Department of Pediatrics, IRCCS Foundation, National Cancer Institute, Milan, Italy
    Q J Nucl Med Mol Imaging 53:526-35. 2009
    ....
  44. ncbi Diagnostic and therapeutic aspects of iatrogenic hypoparathyroidism
    Federica Pallotti
    Nuclear Medicine Division, National Cancer Institute, Milan, Italy
    Tumori 89:547-9. 2003
    ..In this review the most relevant aspects of calcium homeostasis and its alteration in hypoparathyroidism are briefly discussed. In addition, the main approaches to treatment of the hypocalcemic state are presented...
  45. ncbi Critical aspects of immunoradiometric thyroglobulin assays
    Leonardo Ferrari
    Nuclear Medicine Division, National Cancer Institute, Milan, Italy
    Tumori 89:537-9. 2003
    ..Tg values vary widely between assays and the classification of patients according to Tg values with clinical relevance is still dependent on the assay used...
  46. ncbi Diagnostic procedures in the follow-up of patients affected by MEN type 2
    Ettore Seregni
    Division of Nuclear Medicine, National Cancer Institute, Milan, Italy
    Tumori 89:563-5. 2003
    ..In this paper we summarize the most relevant diagnostic methods to detect and monitor MTC, pheochromocytoma and hyperparathyroidism...
  47. ncbi Biochemical characteristics and recent biological knowledge on prostate-specific antigen
    E Seregni
    Nuclear Medicine Department, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy
    Tumori 82:72-7. 1996
    ..These new findings will have implications for the clinical application of PSA as a tumor marker for prostate cancer...
  48. ncbi Prophylactic thyroidectomy in MEN 2A syndrome
    Franco Mattavelli
    Department of Head and Neck Surgery, National Cancer Institute, Milan, Italy
    Tumori 89:553-5. 2003
    ..Our experience has confirmed the presence of CCH and medullary thyroid carcinoma even in clinically negative patients, in agreement with reports in the literature...
  49. ncbi Bone turnover markers and insulin-like growth factor components in metastatic breast cancer: results from a randomised trial of exemestane vs megestrol acetate
    Antonia Martinetti
    Nuclear Medicine Unit, Istituto Nazionale Tumori, Via Venezian 1, 20133 Milan, Italy
    Anticancer Res 23:3485-91. 2003
    ....
  50. ncbi Evaluation of circulating calcitonin: analytical aspects
    Antonia Martinetti
    Nuclear Medicine Division, National Cancer Institute, Milan, Italy
    Tumori 89:566-8. 2003
    ..hCT values are widely dispersed depending on the method used for marker measurement; as a consequence, patient classification according to the hCT cutoff value is still dependent on the assay used...
  51. ncbi Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
    Dario Baratti
    Department of Surgery, National Cancer Institute, Milan, Italy
    Ann Surg Oncol 14:2300-8. 2007
    ..The selection factors predicting clinical outcome are still a matter of clinical investigation. We assessed the prognostic reliability of serum tumor markers in a large series of patients with PMP undergoing CRS and HIPEC...
  52. ncbi Could exemestane affect insulin-like growth factors, interleukin 6 and bone metabolism in postmenopausal advanced breast cancer patients after failure on aminoglutethimide, anastrozole or letrozole?
    Leonardo Ferrari
    Nuclear Medicine Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, I 20133 Milano, Italy
    Int J Oncol 22:1081-9. 2003
    ..The observed variations seem to be mainly linked to the circulating oestrogen levels rather than directly to the way of action of the AI employed...
  53. ncbi Circulating CA125 in patients with peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion
    Dario Baratti
    Department of Surgery, National Cancer Institute, Milan, Italy
    Ann Surg Oncol 14:500-8. 2007
    ..Circulating tumor markers have never been extensively investigated in the management of PM. We assessed the clinical role of markers in a large series of patients with PM undergoing CRS and IPHP...
  54. ncbi The estrogen suppression after sequential treatment with formestane in advanced breast cancer patients
    Nicoletta Zilembo
    Medical Oncology Unit B, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via G. Venezian 1, 20133 Milan, Italy
    Biomed Pharmacother 58:255-9. 2004
    ..This approach can be used in clinical practice in order to offer a disease control with a satisfactory quality of life...
  55. ncbi Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma
    Giuditta Cuccuru
    Preclinical Chemotherapy and Pharmacology Unit, and Nuclear Medicine Unit, Istituto Nazionale Tumori, Milan, Italy
    J Natl Cancer Inst 96:1006-14. 2004
    ..CONCLUSIONS: Ret oncoproteins represent exploitable targets for therapeutic intervention in MEN2A-associated medullary thyroid carcinoma. The antitumor efficacy and oral bioavailability of RPI-1 support its therapeutic potential...
  56. ncbi Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry
    Jinong Li
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    Clin Chem 51:2229-35. 2005
    ..C3a(desArg) appears to lack specificity among patients with benign diseases, limiting its utility as a stand-alone tumor marker, but it may still be useful in a multimarker panel for early detection of breast cancer...